不明原因消化道出血患者胶囊内镜检查后长期再出血率及再出血预测因素
这项单中心观察性研究连续纳入2004年3月至2015年12月因不明原因消化道出血(OGIB)首次接受小肠胶囊内镜(CE)检查的患者389例,通过病历或信件随访。5年累积再出血率为41.7%,显性OGIB、抗凝药、CE后气囊辅助小肠镜阳性发现及未行治疗性干预的铁剂补充与再出血相关,较高的最低血红蛋白水平和治疗性干预降低再出血风险。
要点
- OGIB患者CE检查后5年累积再出血率为41.7%。
- 显性OGIB、抗凝药、CE后气囊辅助小肠镜阳性及未行治疗性干预的铁剂补充与再出血相关。
- 肝硬化是再出血的独立预测因素,CE阴性者中亦如此。
核心结论
- OGIB患者长期随访中再出血常见,肝硬化或既往大量出血的患者需要仔细随访。
研究设计与样本
- 单中心观察性研究,连续纳入2004年3月至2015年12月因OGIB首次接受小肠CE检查的患者,通过病历或信件随访,共389例纳入分析。
主要发现
- 生存曲线分析显示OGIB患者5年累积再出血率为41.7%。
- Cox比例风险模型多因素分析显示,显性OGIB(HR 2.017;95%CI 1.299-3.131;P=.002)、抗凝药(HR 1.930;95%CI 1.093-3.410;P=.023)、CE后气囊辅助小肠镜阳性发现(HR 2.927;95%CI 1.791-4.783;P<.001)及未行治疗性干预的铁剂补充(HR 2.202;95%CI 1.386-3.498;P=.001)与再出血相关。
- 较高的最低血红蛋白水平(HR .902;95%CI .834-.975;P=.009)和治疗性干预(HR .288;95%CI .145-.570;P<.001)显著降低再出血风险。
- Charlson共病指数组分中,肝硬化是OGIB患者再出血的独立预测因素(HR 4.362;95%CI 2.622-7.259;P<.001),在CE阴性患者中亦为独立预测因素(HR 8.961;95%CI 4.424-18.150;P<.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: The incidence of rebleeding in obscure GI bleeding (OGIB) remains unclear. This study used capsule endoscopy (CE) to determine the long-term rebleeding rate and predictive factors for rebleeding in patients with OGIB. METHODS: This single-center, observational study enrolled consecutive patients with OGIB who underwent CE as the first small intestinal examination between March 2004 and December 2015 and were followed up through medical records or letters. RESULTS: Three hundred eighty-nine patients were included in the analysis. Survival curve analysis showed that the overall cumulative rebleeding rate in OGIB during the 5 years was 41.7%. Multivariate analysis using the Cox proportional hazards model revealed that overt OGIB (hazard ratio [HR], 2.017; 95% confidence interval [CI], 1.299-3.131; P = .002), anticoagulants (HR, 1.930; 95% CI, 1.093-3.410; P = .023), positive balloon-assisted enteroscopy findings after CE (HR, 2.927; 95% CI, 1.791-4.783; P < .001), and iron supplements without therapeutic intervention (HR, 2.202; 95% CI, 1.386-3.498; P = .001) were associated with rebleeding, whereas a higher minimum hemoglobin level (HR, .902; 95% CI, .834-.975; P = .009) and therapeutic intervention (HR, .288; 95% CI, .145-.570; P < .001) significantly reduced the risk of rebleeding. Among the Charlson Comorbidity Index components, liver cirrhosis was an independent predictor associated with rebleeding in patients with OGIB (HR, 4.362; 95% CI, 2.622-7.259; P < .001) and in patients with negative CE findings (HR, 8.961; 95% CI, 4.424-18.150; P < .001). CONCLUSIONS: Rebleeding is common during the long-term follow-up of patients with OGIB. Careful follow-up is required for patients with liver cirrhosis or previous massive bleeding.
引用
- Otani K, Shimada S, Watanabe T, et al. Long-term rebleeding rate and predictive factors of rebleeding after capsule endoscopy in patients with obscure GI bleeding. Gastrointest Endosc. 2022. PMID: 35850171. doi:10.1016/j.gie.2022.07.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。